Trebananib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Trebananib
Accession Number
DB12056
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon Cancer, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
Amg 386
Categories
UNII
X8Y5U6NC7E
CAS number
894356-79-7

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Alendronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Alendronic acid.
Clodronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Clodronic acid.
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trebananib.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trebananib.
Etidronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Etidronic acid.
IbandronateThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Ibandronate.
Incadronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Incadronic acid.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trebananib.
Pamidronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Pamidronic acid.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Trebananib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911276

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Solid Neoplasm / Lung Carcinoid Tumor / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Uterine Corpus Sarcoma / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IV Renal Cell Cancer / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma1
1CompletedTreatmentAdvanced Solid Tumors2
1CompletedTreatmentAdvanced Solid Tumors / Impaired Renal Function / Kidney Diseases1
1CompletedTreatmentBreast Cancer / Locally Recurrent and Metastatic Breast Cancer / Malignancies / Metastases / Metastatic Cancers / Neoplasms, Breast / Oncology / Tumors / Tumors, Breast / Tumors, Solid1
1CompletedTreatmentCarcinoma NOS / Fallopian Tube Cancer / Gynecological Malignancies / Malignancies / Metastases / Oncology / Ovarian Cancer / Tumors / Tumors, Solid1
1CompletedTreatmentCarcinoma NOS / Fallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer1
1CompletedTreatmentCentral Nervous System Neoplasms / Solid Neoplasms1
1CompletedTreatmentNeoplasms, Advanced Solid1
1CompletedTreatmentTumors1
1RecruitingTreatmentAdvanced Solid Tumors1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentAdult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Oligodendroglioma / Giant Cell Glioblastoma / Glioblastomas / Gliosarcoma / Oligodendrogliomas / Recurrent Adult Brain Neoplasm / Recurrent Brain Neoplasm / Recurrent Glioblastoma1
2Active Not RecruitingTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer1
2Active Not RecruitingTreatmentRenal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage III Renal Cell Cancer AJCC v7 / Stage IV Renal Cell Cancer / Stage IV Renal Cell Cancer AJCC V71
2CompletedTreatmentAdult Angiosarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentAdvanced Hepatocellular Carcinoma / Inoperable Hepatocellular Carcinoma1
2CompletedTreatmentAdvanced Renal Cell Carcinoma2
2CompletedTreatmentCarcinoma NOS / Colorectal Cancers / Gastrointestinal Cancers / Malignancies / Malignant Neoplasm of Colon / Metastases / Metastatic Cancers / Metastatic Colorectal Cancer (MCRC) / Oncology / Rectal Carcinoma1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Endometrioid Stromal Sarcoma / Recurrent Uterine Corpus Carcinoma1
2CompletedTreatmentGastrointestinal Cancers1
2CompletedTreatmentLocally Recurrent and Metastatic Breast Cancer1
2CompletedTreatmentProstate Cancer / Prostate Neoplasms / Prostatic Neoplams / Prostatic Neoplasms1
2RecruitingTreatmentBreast Cancer / Neoplasms, Breast / Tumors, Breast1
2Unknown StatusTreatmentMetastatic Colorectal Cancer (MCRC)1
2WithdrawnTreatmentTransitional Cell Carcinoma1
3CompletedTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer1
3TerminatedTreatmentFallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Cancer1
3TerminatedTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:16 / Updated on December 02, 2019 09:17